Roche Holding AG Deal History & Licensing Activity
Roche Holding AG is a life sciences. Over the past three years, Roche Holding AG has been involved in 3 licensing and acquisition transactions, with a primary focus on Other (3 deals).
Deals (12mo)
2
Active Trials
0
Top Modality
Other
Focus Area
Codev Deals
Roche Holding AG Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Roche Holding AG in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| Zenapax (asthma/respiratory disorders) | Roche | Antibodies | Unknown | co development | Jul 12, 2026 |
| PathAI digital pathology platform | PathAI | Other | Unknown | acquisition | Jul 10, 2026 |
Roche Holding AG Pipeline Focus
Therapeutic areas and modalities where Roche Holding AG is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
See How Your Asset Matches Roche Holding AG's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Codev Deals assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Other Benchmarks
Upfront, milestone, and royalty benchmarks for other deals
Antibodies Benchmarks
Upfront, milestone, and royalty benchmarks for antibodies deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Roche Holding AG Licensing & Deal Activity
Roche Holding AG is a life sciences company that has been actively engaged in licensing transactions across the biopharma landscape. With 3 deals over the past three years, Roche Holding AG ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Roche Holding AG include Codev Deals (3 deals and trials), and Mega Deals (2 deals and trials). In terms of modality, Roche Holding AG has shown particular interest in other, antibodies.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Roche Holding AG and 850+ other biopharma companies. Use our Solidus to benchmark your asset against Roche Holding AG's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.